Understanding how Trop2 affects aggressive prostate cancer
Elucidating the Role of Trop2 in Prostate Cancer
This study is looking at a protein called Trop2 to understand how it helps advanced prostate cancer grow, especially when it stops responding to hormone therapy, with the goal of finding better treatment options for patients like you.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-10976986 on NIH RePORTER |
What this research studies
This research investigates the role of a protein called Trop2 in the progression of advanced prostate cancer, particularly in cases that become resistant to hormone therapy. The study aims to uncover the molecular mechanisms by which Trop2 contributes to the development of aggressive forms of the disease. By focusing on Trop2, researchers hope to identify new therapeutic strategies that could improve treatment outcomes for patients with advanced prostate cancer. The research will involve laboratory experiments to analyze the behavior of Trop2 in cancer cells.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with advanced prostate cancer, particularly those whose disease has become resistant to hormone therapy.
Not a fit: Patients with early-stage prostate cancer or those who do not have aggressive forms of the disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that significantly improve survival rates for patients with aggressive prostate cancer.
How similar studies have performed: Previous research has shown promising results in targeting similar molecular pathways in other cancers, suggesting that this approach could be effective for prostate cancer as well.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Stoyanova, Tanya I — University of California Los Angeles
- Study coordinator: Stoyanova, Tanya I
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.